Ovintiv Inc. (OVV)

Positive revenue growth while VET is negative. John Neff might see a notable competitive edge here.

Positive gross profit growth while VET is negative. John Neff would see a clear operational edge over the competitor.

Positive EBIT growth while VET is negative. John Neff might see a substantial edge in operational management.

Positive operating income growth while VET is negative. John Neff might view this as a competitive edge in operations.

Positive net income growth while VET is negative. John Neff might see a big relative performance advantage.

Positive EPS growth while VET is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.

Positive diluted EPS growth while VET is negative. John Neff might view this as a strong relative advantage in controlling dilution.

Share reduction more than 1.5x VET's 0.17%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.

No Data available this quarter, please select a different quarter.

Positive OCF growth while VET is negative. John Neff would see this as a clear operational advantage vs. the competitor.

Positive FCF growth while VET is negative. John Neff would see a strong competitive edge in net cash generation.

5Y revenue/share CAGR above 1.5x VET's 179.55%. David Dodd would look for consistent product or market expansions fueling outperformance.

3Y revenue/share CAGR above 1.5x VET's 45.64%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.

5Y OCF/share CAGR above 1.5x VET's 146.39%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.

3Y OCF/share CAGR 1.25-1.5x VET's 159.61%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.

5Y net income/share CAGR above 1.5x VET's 445.23%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.

3Y net income/share CAGR above 1.5x VET's 59.38%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.

10Y equity/share CAGR above 1.5x VET's 289.92%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.

5Y equity/share CAGR above 1.5x VET's 116.20%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.

3Y equity/share CAGR above 1.5x VET's 55.75%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.

5Y dividend/share CAGR above 1.5x VET's 24.26%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.

3Y dividend/share CAGR above 1.5x VET's 11.67%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.

Inventory is declining while VET stands at 197.46%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.

Asset growth above 1.5x VET's 0.40%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.

BV/share growth above 1.5x VET's 7.45%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.

No Data available this quarter, please select a different quarter.

We cut SG&A while VET invests at 4.29%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.